Interview with Dr. Alex Zhavoronkov, Co-founder and CEO Insilico Medicine

Insilico Medicine recently announced a major breakthrough where its end-to-end artificial intelligence (AI) system discovered a novel molecule for a novel target relevant for Idiopathic Pulmonary Fibrosis (IPF). The molecule demonstrated efficacy in vivo and reached the status of a preclinical drug candidate. The clinical trial is planned for the end of the year or the beginning of 2022.